S&P Futures
4,634.00 -20.75 (-0.45%) Dow Futures
35,736.00 -60.00 (-0.17%) Nasdaq Futures
15,444.75 -151.00 (-0.97%) Russell 2000 Futures
2,151.10 -6.60 (-0.31%) Crude Oil
85.48 +1.66 (+1.98%) Gold
1,816.00 -0.50 (-0.03%)
BioAtla, Inc. (BCAB)
After hours:
Chart Events
Performance Outlook
| Previous Close | 12.82 |
| Open | 12.62 |
| Bid | 0.00 x 800 |
| Ask | 0.00 x 1000 |
| Day's Range | 11.96 - 13.08 |
| 52 Week Range | 11.96 - 76.63 |
| Volume | |
| Avg. Volume | 290,727 |
| Market Cap | 465.236M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.16 |
| Earnings Date | Mar 22, 2022 - Mar 28, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 67.40 |
Fair Value
Related Research
- BioAtla, Inc.Daily – Vickers Top Buyers & Sellers for 12/01/2021The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.RatingFair ValueEconomic Moat2 months agoArgus Research
- PR Newswire
BioAtla Announces Clinical Collaboration with Bristol Myers Squibb to Study Mecbotamab Vedotin (BA3011) and Ozuriftamab Vedotin (BA3021) in Combination with Opdivo® (nivolumab) for Treatment of Solid Tumors
BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics, today announced that it has entered into a clinical collaboration with Bristol Myers Squibb (NYSE: BMY) to investigate BioAtla's two lead CAB-ADC candidates, BA3011 and BA3021, in combination with Bristol Myers Squibb's anti-PD-1 therapy Opdivo® (nivolumab).
- PR Newswire
BIOATLA APPOINTS EDWARD L. WILLIAMS TO BOARD OF DIRECTORS
BioAtla, Inc., a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics, today announced that Edward L. (Eddie) Williams has been appointed to the BioAtla Board of Directors and has agreed to serve on the Audit Committee of the Board. Mr. Williams has extensive executive experience in the biopharmaceutical industry and as a member of the board of directors of a biotechnology company in late-stage clinical development. J
- Simply Wall St.
Here's Why We're Not Too Worried About BioAtla's (NASDAQ:BCAB) Cash Burn Situation
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
